Overall, this is the first study to define the cellular mechanisms driving improvements in bone volume in both naïve and myeloma‐bearing mice treated with the novel LRP6 receptor targeting antibody, anti‐LRP6. The gene discussed is LRP6; the disease is plasma cell myeloma.